Vatelizumab
- Generic Name
- Vatelizumab
- Drug Type
- Biotech
- CAS Number
- 1238217-55-4
- Unique Ingredient Identifier
- A4R7G50030
- Background
Vatelizumab has been used in trials studying the treatment of Ulcerative Colitis.
Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839
- First Posted Date
- 2014-12-03
- Last Posted Date
- 2016-12-21
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 62
- Registration Number
- NCT02306811
- Locations
- ๐บ๐ธ
Investigational Site Number 840007, Ormond Beach, Florida, United States
๐ท๐บInvestigational Site Number 643005, Nizhniy Novgorod, Russian Federation
๐ท๐บInvestigational Site Number 643009, Moscow, Russian Federation
Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis
- Conditions
- Relapsing-remitting Multiple Sclerosis
- Interventions
- Drug: Placebo (for Vatelizumab)
- First Posted Date
- 2014-08-22
- Last Posted Date
- 2016-12-21
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 112
- Registration Number
- NCT02222948
- Locations
- ๐บ๐ธ
Investigational Site Number 840004, Cullman, Alabama, United States
๐บ๐ธInvestigational Site Number 840005, Fort Collins, Colorado, United States
๐บ๐ธInvestigational Site Number 840001, Latham, New York, United States
Long Term Safety And Tolerability Of SAR339658 In Patients With Ulcerative Colitis (UC)
- First Posted Date
- 2013-05-23
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 6
- Registration Number
- NCT01861249
- Locations
- ๐บ๐ธ
Investigational Site Number 840008, Miramar,, Florida, United States
๐บ๐ธInvestigational Site Number 840048, Winter Park, Florida, United States
๐บ๐ธInvestigational Site Number 840088, San Antonio, Texas, United States
Efficacy and Safety of SAR339658 in Patients With Moderate to Severe Ulcerative Colitis
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2016-07-13
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 28
- Registration Number
- NCT01659138
- Locations
- ๐บ๐ธ
Investigational Site Number 840071, Rochester, New York, United States
๐บ๐ธInvestigational Site Number 840065, Sun City, Arizona, United States
๐บ๐ธInvestigational Site Number 840059, Mission Hills, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.